Sun Pharma expects India business to stabilise this fiscal
Sun Pharma expects its India business to stabilise in the current fiscal leading to reasonable volume growth after witnessing disruptions in 2017-102-10-2018
02-10-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Valia01-10-2018
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Sun Pharmaceutical Industries Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here28-09-2018
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Submission of Voting Results of Twenty Sixth Annual General Meeting of the Company held on September 26, 2018 in accordance with Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Scrutinizer''s Report.27-09-2018
Chairman Speech At The 26Th Annual General Meeting Of Sun Pharmaceutical Industries Ltd.
Text of the speech delivered by chairman at the 26th Annual General Meeting of Sun Pharmaceutical Industries Ltd., held on September 26, 201827-09-2018
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 26th Annual General Meeting of Sun Pharmaceutical Industries Limited held on September 26, 2018 and intimation of Change in Directors of the Company pursuant to Clause 13 and 7 of Para A of Part A of Schedule III of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') respectively.26-09-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Family Investment Pvt Ltd25-09-2018
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayant Sanghvi21-09-2018
Sun Pharma gets Australian health regulator's nod for plaque psoriasis drug
Drug major Sun Pharmaceutical Industries on Friday said it has received approval from the Australian health regulator, the Therapeutic Goods Administ21-09-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to Australian TGA approval of ILUMYA, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,21-09-2018